Research ArticleHEALTH AND MEDICINE
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
- View ORCID ProfileC. Ämmälä1,*,
- W. J. Drury III1,
- View ORCID ProfileL. Knerr1,
- I. Ahlstedt1,
- P. Stillemark-Billton1,
- C. Wennberg-Huldt1,
- View ORCID ProfileE.-M. Andersson1,
- View ORCID ProfileE. Valeur1,
- R. Jansson-Löfmark1,
- D. Janzén1,
- L. Sundström2,
- J. Meuller2,
- View ORCID ProfileJ. Claesson2,
- View ORCID ProfileP. Andersson3,
- C. Johansson3,
- View ORCID ProfileR. G. Lee4,
- View ORCID ProfileT. P. Prakash4,
- View ORCID ProfileP. P. Seth4,*,
- B. P. Monia4 and
- View ORCID ProfileS. Andersson1
- 1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
- ↵*Corresponding author. Email: carina.ammala{at}astrazeneca.com (C.Ä.); pseth{at}ionisph.com (P.P.S.)
See allHide authors and affiliations
Science Advances 17 Oct 2018:
Vol. 4, no. 10, eaat3386
DOI: 10.1126/sciadv.aat3386
Vol. 4, no. 10, eaat3386
DOI: 10.1126/sciadv.aat3386
C. Ämmälä
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
W. J. Drury III
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
L. Knerr
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
I. Ahlstedt
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
P. Stillemark-Billton
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
C. Wennberg-Huldt
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
E.-M. Andersson
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
E. Valeur
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
R. Jansson-Löfmark
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
D. Janzén
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
L. Sundström
2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
J. Meuller
2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
J. Claesson
2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
P. Andersson
3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
C. Johansson
3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
R. G. Lee
4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
T. P. Prakash
4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
P. P. Seth
4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
B. P. Monia
4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
S. Andersson
1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.